Who checked GHK-Cu for harm?
Promise Peptides prescribes GHK-Cu; the decision rests with its clinician.
mypromise.comIts GHK-Cu product needs a clinician's prescription.
Its licensed U.S. clinicians weigh every case, and they decline some requests.
Its clinicians see only U.S. patients, and their prescribing options differ across states and treatments.
Its GHK-Cu is compounded medicine and has no FDA approval.
A living cell, a comfortable face and a safe medicine are different things to establish. The cell-survival result sounded reassuring. Human studies made the safety question harder to close.
The cell-survival test
In a 2023 experiment, human epidermal cells exposed to liposomal GHK-Cu showed no cytotoxicity, alongside inhibition of elastase. Cytotoxicity means damage that kills cells; elastase breaks down elastin, the protein that helps skin spring back. The tiny lipid carriers also stayed stable for four weeks at room temperature. Those are useful findings for a formulation experiment.
I overestimated the comfort that cell-survival result would bring. The test setting complicated it. The experiment tested a particular preparation against particular measures in cultured cells. A face can itch while its cells remain alive. A medicine can raise questions about exposure elsewhere in the body. Each of those calls for a different observation.
An all-clear overstates the cell-survival finding, I think. The liposome study gives a reason to continue investigating that preparation. Its cell-survival result leaves human irritation and prolonged systemic exposure open.
The post-laser trial
The human record has a useful complication. In a trial involving 13 people after CO2 laser resurfacing, measured redness showed no statistically significant difference between treatment and control. Satisfaction was significantly higher in the GHK-Cu group.
That split deserves to survive intact. I take the satisfaction seriously, and the measured redness just as seriously. Neither outcome supplies a general rate of side effects. The trial concerns freshly treated skin and a topical preparation, a much narrower setting than the safety claims attached to this peptide.
Cosmetic permission
GHK-Cu combines the three-amino-acid peptide GHK with copper. It appears on cosmetic ingredient lists as Copper Tripeptide-1 and has a long history in topical skin products. Cosmetics in the US, EU and UK may contain it. GHK-Cu has no FDA- or EMA-approved drug indication; injectable and systemic uses remain unapproved.
Legal is an awkward word to put in a site name. I enjoy the nuisance it creates: permission for which use? A cosmetic ingredient's status answers a regulatory question about that use. Human pharmacokinetics—how a substance moves through and leaves the body—would answer a separate question about exposure. That human GHK-Cu record remains missing.
Skin reactions and body exposure
The most immediate questions are familiar ones: redness, stinging, itching, dryness and breakouts. People also describe dark spots changing in either direction. These are anecdotal accounts, without a trial population from which to calculate the chance of a reaction. The GHK-Cu peptide side effects page puts the complaints beside the published safety findings.
For a different problem, the dosage and half-life file follows the often-repeated blood estimate back to the distinction between free GHK and GHK-Cu. The community accounts have their own place. I have trouble accepting either dismissal or reassurance when the observation needed to settle the question has yet to be made.